Pfizer (PFE) 10-K2023 FY Annual report

Filed: 22 Feb 24, 1:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Abrysvo, ADC, adversarial, AKS, Alexandre, Alexion, allosteric, analgesia, analyst, anesthesia, artificial, assembled, asterisk, attention, awaiting, background, BCR, belief, biased, biochemical, Blackstone, blaylock, bone, Boshoff, Bravo, BRCA, broadly, cap, Castle, catastrophic, ceiling, celebrate, cervical, chart, Chase, circulating, CISO, clarity, colorectal, combo, confirmatory, contemplation, controversial, COVID, crime, crucial, cultivate, cybersecurity, dan, de, deficient, deflation, depth, difficulty, disaster, Disitamab, donut, EAP, echevarria, ecosystem, Elrexfio, embedded, empowerment, endemic, enfortumab, enterprise, ERM, expedite, fitelparvovec, flawed, fluoropyrimidine, footnote, gastrointestinal, Genevant, genitourinary, Genmab, Germay, giroctocogene, graft, gynecological, harnessing, Healthier, helen, hematologic, HRR, HRSA, Hungary, Ignite, importantly, inappropriate, incentivize, inconsistency, Indenture, inefficiency, Inline, inoperable, instance, intelligence, intranasal, intrusion, irrevocably, Israeli, joseph, JPMorgan, Kepro, kinase, licensee, licensure, lifecycle, Linkbase, Litfulo, littman, Lucira, madden, Majorelle, Manhattan, margaret, Mellon, misuse, morale, Mount, mutual, nasal, navigate, NC, Ngenla, nmCSPC, Nonfunded, Nordisk, Novo, OECD, OIG, OMI, omnichannel, opportunistic, ORD, overseeing, oxaliplatin, Padcev, page, pembrolizumab, penetration, PIE, Pillar, pledged, Poland, poor, PRD, priority, prompt, protocol, ransomware, recessionary, recombination, recurrence, recurrent, RemeGen, remuneration, rephasing, Republic, retaliation, retention, revolutionizing, Rocky, Romania, ronald, rotation, RSV, satisfaction, Schema, scrutinize, Seagen, seasonal, secondary, sense, signature, singly, smith, SMPA, Somavert, spray, stockpile, streamlining, struggling, Sumitomo, surface, suspected, syndrome, Synthon, Takeda, Taxonomy, Telavant, thoracic, tisotumab, Tivdak, toolkit, tornado, touch, training, Transplant, trastuzumab, triage, true, tucatinib, Tukysa, tyrosine, ULC, Ulcerative, unaudited, unconditionally, unconsolidated, underinsured, undersigned, underway, unidentified, uninsured, unintended, uninterrupted, unveiled, upcoming, urology, urothelial, utmost, vast, vedotin, Velsipity, Vepdegestrant, Vigilance, XBRL, Zai, Zavzpret

Removed: accommodate, accruing, Anacor, Angela, antibody, Asian, Aug, automation, bioequivalence, bioequivalent, Biogen, buyer, castration, center, CMA, convertible, CStone, Dec, denominated, derecognition, derecognized, direction, disgorgement, disputed, distributed, domestically, enforced, ethically, Eucrisa, evenly, eventual, Feb, fiduciary, Glenmark, great, headquartered, Hwang, indirect, Jan, methodology, Myovant, NASDAQ, neighborhood, Nexium, Nov, NRDL, obligor, Oct, officially, oncological, ordered, originator, Overnight, par, Parcel, pause, payer, Peapack, perpetual, prevalent, proposing, prospectively, protease, proton, Protonix, PTSRU, pump, reallocated, reallocating, redeem, redeploy, renamed, repay, repurchased, restitution, Retacrit, RSC, Secured, separated, simplify, SOFR, Spiral, sugemalimab, superseded, Sutent, transformed, travel, treating, underwritten, unified, University, vaccinated, venture, widespread, William, WPP

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PFE transcripts

PFE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, I, David M. Denton, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.


/s/DAVID M. DENTON
David M. Denton
Chief Financial Officer, Executive Vice President

February 22, 2024

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.